10
Participants
Start Date
June 1, 2017
Primary Completion Date
March 27, 2019
Study Completion Date
March 27, 2019
Maraviroc
Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
Institute of Human Virology at the University of Maryland School of Medicine, Baltimore
Collaborators (1)
ViiV Healthcare
INDUSTRY
University of Maryland, Baltimore
OTHER